Abbott Laboratories announced on Thursday that its net sales in the second quarter of the fiscal year 2024 observed an annual rise of 4.0% to hit $10.4 billion. On the other hand, its net earnings declined by 5.3% compared to the same trimester the year before to reach $1.3 billion. Meanwhile, its diluted earnings per share (EPS) worsened by 5.1% to $0.74.
"We achieved another quarter of strong growth in our underlying base business," Chairman and Chief Executive Officer (CEO) Robert B. Ford commented. "We have a lot of positive momentum heading into the second half of the year and are raising our full-year guidance."
Following the release of the report, Abbott's shares decreased by 0.64% during premarket trading.
